Clinical Trials Logo

Dwarfism, Pituitary clinical trials

View clinical trials related to Dwarfism, Pituitary.

Filter by:

NCT ID: NCT00596037 Completed - Clinical trials for Adult Growth Hormone Deficiency

Treatment of Adults With Growth Hormone Deficiency

Start date: August 2006
Phase: Phase 3
Study type: Interventional

The objective of this rollover study is to evaluate the long term (1 year) safety of a new weekly administered growth hormone preparation in adults with growth hormone deficiency who were treated with the same experimental preparation in study BPLG-005. In addition, further change in efficacy endpoints of BPLG-005 by prolonged treatment will be evaluated. Additional efficacy and safety data of the experimental preparation will be obtained from the switch-over patients.

NCT ID: NCT00591760 Completed - Heart Failure Clinical Trials

Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary Trial

Start date: December 2004
Phase: Phase 2
Study type: Interventional

The aim of this study is to investigate the potential benefits of the correction of growth hormone (GH) deficiency with GH replacement therapy in patients with chronic heart failure due to left ventricular systolic dysfunction.

NCT ID: NCT00570011 Completed - Clinical trials for Growth Hormone Deficiency

Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients

Start date: June 1997
Phase: Phase 3
Study type: Interventional

An international study in which patients with GHD were randomized to receive somatropin at a dose of either 3 microg/kg/day or 6 microg/kg/day for the first three months. The dose was then doubled (6 microg/kg/day, LD or 12 microg/kg/day, CD) for the next three-months.

NCT ID: NCT00567385 Completed - Clinical trials for Growth Hormone Disorder

Liquid Somatropin Formulation in Children With Growth Hormone Deficiency

Start date: March 10, 2003
Phase: Phase 4
Study type: Interventional

This trial is conducted in Europe. The aim of this trial is to evaluate the acceptance of the new liquid growth hormone formulation, somatropin, in children with growth hormone deficiency.

NCT ID: NCT00562796 Completed - Obesity Clinical Trials

Prevalence and Cardiovascular Effects of Growth Hormone Deficiency in Abdominal Obesity

Start date: November 2007
Phase: N/A
Study type: Observational

Obesity is one of the leading causes of cardiovascular-related diseases, including diabetes and heart disease. Obesity, and more specifically abdominal obesity, may cause decreased growth hormone (GH) levels. It is believed that GH deficiency may contribute to increased cardiovascular risk by affecting insulin resistance, inflammatory markers, and blood cholesterol levels. This study will determine the occurrence of GH deficiency in abdominal obesity and whether GH deficiency is associated with increased cardiovascular risk beyond traditional risk factors.

NCT ID: NCT00519558 Completed - Clinical trials for Adult Growth Hormone Deficiency

Growth Hormone Deficiency in Adults (GHDA)

Start date: May 31, 2003
Phase: Phase 3
Study type: Interventional

This trial is conducted in Japan. The aim of this trial is to demonstrate superiority of the effect of NN-220 compared with that of placebo as assessed by the change in percent in truncal fat (kg) from baseline to 24 weeks' treatment (end of treatment) in patients with Growth Hormone Deficiency in Adults (GHDA).

NCT ID: NCT00517062 Completed - Clinical trials for Growth Hormone Deficiency

Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates

Start date: January 2006
Phase: Phase 0
Study type: Interventional

Study hypothesis: Growth hormone (GH), through its generation of free 'bioavailable' insulin-like growth factor (IGF)-I, can improve insulin sensitivity in adults with GH deficiency. Study aims: The purpose of this study is to determine the mechanism of how low dose GH treatment affects the body's sensitivity to insulin actions and whether this low GH dose can affect the body's handling of steroid hormone levels (cortisol clearance) in adults with GH deficiency. Study design: Men and women with confirmed GH deficiency, but not recently been on GH treatment will be invited to participate in this study. The subjects will be assessed at the initial visit to ascertain their suitability before further participating in the study. If suitable, an equal number of men and women will be randomized to receive either low dose GH or placebo injection for 3 months. Before, during and after treatment, the subjects will be assessed at regularly with blood tests, scans and fat biopsies. At the first and final visit, testing will include scans to measure the amount of whole body fat and fat in the stomach area, muscle, and liver; blood tests to measure levels of cortisol, and fat tissue (taken from a biopsy) analysis to measure the density of IGF-I in the muscle; whereas blood tests to examine insulin sensitivity will also be collected. This study will use Genotropin and Genotropin pen devices, and the the data will be analyzed using a computer statistical program where the identity of the subjects will be coded to maintain confidentiality.

NCT ID: NCT00511927 Completed - Heart Failure Clinical Trials

Growth Hormone Deficiency in Chronic Heart Failure: an Observational Study

Start date: July 2010
Phase: N/A
Study type: Observational

Aim of this study is to define the possible detrimental effect of a lack of growth hormone, on the well-being and life expectation of patients affected by heart failure.

NCT ID: NCT00497562 Completed - Fibromyalgia Clinical Trials

Growth Hormone as Add-on Treatment in Severe Fibromyalgia With Low IGF-1 Serum Levels (56 Characters)

Start date: May 2004
Phase: Phase 2
Study type: Interventional

There are evidences of functional growth hormone (GH) deficiency, expressed by means of low serum levels of insulin-like growth factor 1 (IGF-1), in a subset of fibromyalgia patients. The efficacy of low GH doses versus placebo has been demonstrated in this population. We assessed the efficacy and safety of GH added to standard therapy compared to standard therapy alone in the treatment of severe, prolonged and well-treated fibromialgya patients with low IGF-1 levels.

NCT ID: NCT00491582 Completed - Clinical trials for Growth Hormone Deficiency

The Effects of Growth Hormone (GH) on Lipid Depots

Start date: July 2007
Phase: N/A
Study type: Interventional

This study aims at investigating the effect of growth hormone on lipid-content of muscle and liver as well as visceral fat mass in relation to insulin sensitivity. In addition, hormonal regulation and free fatty availability is assessed during a physical exercise at 50-60% VO2max. Finally, the value of physical exercise in diagnosing growth hormone deficiency is investigated. Hypothesis: 1) Lipid content of muscle and liver change with physical exercise and exercise capacity and free fatty availability will influence these changes. 2)Growth hormone replacement therapy will predominantly reduce visceral fat mass and increase free fatty availability. 3)Free fatty availability during exercise will be reduced in growth hormone deficient patients 4)Physical exercise may be an alternative way to diagnose growth hormone deficiency